Yorktown Management & Research Co Inc Takes Position in Progyny, Inc. $PGNY

Yorktown Management & Research Co Inc acquired a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 11,500 shares of the company’s stock, valued at approximately $253,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Progyny during the 1st quarter valued at about $354,000. Nordea Investment Management AB increased its stake in shares of Progyny by 0.6% during the 2nd quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock valued at $4,052,000 after acquiring an additional 1,140 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Progyny by 233.9% during the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company’s stock valued at $120,000 after acquiring an additional 3,768 shares during the last quarter. Voya Investment Management LLC increased its stake in shares of Progyny by 258.2% during the 1st quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock valued at $4,144,000 after acquiring an additional 133,703 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of Progyny by 7.5% during the 1st quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock valued at $29,107,000 after acquiring an additional 90,367 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PGNY shares. Leerink Partners raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 target price for the company in a research report on Tuesday, July 8th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Canaccord Genuity Group increased their target price on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 20th. JPMorgan Chase & Co. increased their target price on shares of Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. Finally, Truist Financial increased their target price on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.44.

Progyny Stock Down 1.5%

Shares of NASDAQ:PGNY opened at $19.23 on Wednesday. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $26.76. The company has a 50 day moving average of $21.56 and a two-hundred day moving average of $22.00. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of 32.59, a price-to-earnings-growth ratio of 1.66 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. During the same period last year, the business earned $0.17 EPS. The firm’s revenue was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, equities analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Activity at Progyny

In other Progyny news, EVP Allison Swartz sold 2,398 shares of the stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the sale, the executive vice president owned 79,697 shares of the company’s stock, valued at $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kevin K. Gordon sold 2,500 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the sale, the director directly owned 12,501 shares of the company’s stock, valued at $275,522.04. This trade represents a 16.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,895 shares of company stock valued at $179,311 in the last ninety days. 9.40% of the stock is owned by corporate insiders.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.